The only approved CAR-T is anti-CD19 for the treatment of B-cell lymphoma, which targets the co-stimulatory molecule CD19 in B-cell lymphoma and leukemia [272]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.